NASDAQ:VRCA • US92511W2070
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERRICA PHARMACEUTICALS INC (VRCA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-18 | Brookline Capital | Upgrade | Hold -> Buy |
| 2025-05-14 | Needham | Reiterate | Hold -> Hold |
| 2025-04-09 | Needham | Reiterate | Hold -> Hold |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-12 | Needham | Reiterate | Hold -> Hold |
| 2024-12-20 | Needham | Reiterate | Hold -> Hold |
| 2024-11-06 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-05 | Needham | Reiterate | Hold |
| 2024-11-05 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-10-21 | TD Cowen | Maintains | Buy -> Buy |
| 2024-10-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-03 | Needham | Downgrade | Buy -> Hold |
| 2024-10-02 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-08-15 | Needham | Maintains | Buy -> Buy |
| 2024-08-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-05-14 | Needham | Maintains | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-01 | Needham | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-15 | Jefferies | Reiterate | Buy -> Buy |
| 2023-11-10 | Needham | Maintains | Buy -> Buy |
| 2023-10-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-23 | Needham | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.124M -43.26% | 7.566M 47.66% | 35.577M 370.22% | 25.633M -27.95% | 49.246M 92.12% | 88.97M 80.66% | 172.79M 94.21% | 198.39M 14.82% | 229.76M 15.81% | 243.27M 5.88% | 254.44M 4.59% | |
| EBITDA YoY % growth | -62.672M -200.73% | -64.875M -3.52% | -11.454M 82.34% | -25.092M -119.07% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -63.222M -196.96% | -65.836M -4.13% | -11.939M 81.87% | -25.161M -110.75% | -10.963M 56.43% | 18.819M 271.66% | 84.813M 350.68% | 105.16M 23.99% | 127.65M 21.39% | 129.13M 1.16% | 135.2M 4.70% | |
| Operating Margin | -1,233.84% | -870.16% | -33.56% | -98.16% | -22.26% | 21.15% | 49.08% | 53.01% | 55.56% | 53.08% | 53.14% | |
| EPS YoY % growth | -14.60 -84.81% | -15.40 -5.48% | -1.47 90.45% | -1.21 17.96% | -0.19 83.93% | 6.22 3,310.53% | 3.47 -44.26% | 3.77 8.82% | 3.88 2.70% | 3.72 -3.95% | 3.57 -4.11% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.48 52.43% | -0.39 -2,038.00% | -0.35 -1,073.00% | -0.31 32.37% |
| Revenue Q2Q % growth | 4.998M 46.05% | 6.936M -45.39% | 7.65M -46.67% | 9.384M 84.29% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.936M 14.69% | -5.763M -481.66% | -2.703M -266.13% | -5.151M 25.84% |
All data in USD
11 analysts have analysed VRCA and the average price target is 16.83 USD. This implies a price increase of 284.25% is expected in the next year compared to the current price of 4.38.
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of VERRICA PHARMACEUTICALS INC (VRCA) is -0.48 USD and the consensus revenue estimate is 5.00M USD.
The expected long term growth rate for VERRICA PHARMACEUTICALS INC (VRCA) is 35.48%.